0000899243-21-039941.txt : 20211012 0000899243-21-039941.hdr.sgml : 20211012 20211012193609 ACCESSION NUMBER: 0000899243-21-039941 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211008 FILED AS OF DATE: 20211012 DATE AS OF CHANGE: 20211012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ehrlich Christopher B CENTRAL INDEX KEY: 0001293973 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40877 FILM NUMBER: 211319797 MAIL ADDRESS: STREET 1: 499 ILLINOIS STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PHOENIX BIOTECH ACQUISITION CORP. CENTRAL INDEX KEY: 0001870404 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 871088814 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2001 MARKET STREET STREET 2: SUITE 3400 CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 2157319450 MAIL ADDRESS: STREET 1: 2001 MARKET STREET STREET 2: SUITE 3400 CITY: PHILADELPHIA STATE: PA ZIP: 19103 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-10-08 0 0001870404 PHOENIX BIOTECH ACQUISITION CORP. PBAX 0001293973 Ehrlich Christopher B 2201 BROADWAY, SUITE 705 OAKLAND CA 94612 1 1 1 0 CEO and Secretary Class A common stock 2021-10-08 4 J 0 36733 10.00 A 699996 I By Phoenix Biotech Sponsor, LLC Class B Common Stock 2021-10-08 4 J 0 82875 D Class A Common Stock 82875 4596250 I By Phoenix Biotech Sponsor, LLC Warrants 11.50 2021-10-08 4 J 0 18366 0.00 A Class A Common Stock 18366 349998 I By Phoenix Biotech Sponsor, LLC Acquisition by the issuer's sponsor, Phoenix Biotech Sponsor, LLC (the "Sponsor") in connection with the partial exercise of the underwriters' over-allotment option. These shares underlie the same number of units of the issuer held by the reporting person. The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. Forfeiture and cancellation of shares of Class B common stock for no consideration because the underwriters' over-allotment option was not exercised in full. These securities are held directly by the Sponsor, which managed by the reporting person. As a result, all of the securities may be deemed to be beneficially held by the reporting person. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose. The warrants will become exercisable at the later of 30 days after the consummation of the issuer's initial business combination or 12 months from the completion of the issuer's initial public offering. The warrants will expire five years after the consummation of the issuer's initial business combination or earlier upon redemption of all of the issuer's outstanding Class A common shares or the issuer's liquidation. /s/ Chris Ehrlich 2021-10-12